Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

FDA Deals Second Setback to AstraZeneca/ZS Pharma Hyperkalemia Candidate ZS-9

AstraZeneca acknowledged today that its NDA for ZS-9 (sodium zirconium cyclosilicate)—the hyperkalemia drug candidate it is co-developing with its ...

Forward this item to a colleague:


(Separate multiple addresses by commas)